[go: up one dir, main page]

MX2010001075A - Derivados de n-piperidin-4-ilmetil-amida y su uso como inhibidores de recaptacion del neurotransmisor de monoamina. - Google Patents

Derivados de n-piperidin-4-ilmetil-amida y su uso como inhibidores de recaptacion del neurotransmisor de monoamina.

Info

Publication number
MX2010001075A
MX2010001075A MX2010001075A MX2010001075A MX2010001075A MX 2010001075 A MX2010001075 A MX 2010001075A MX 2010001075 A MX2010001075 A MX 2010001075A MX 2010001075 A MX2010001075 A MX 2010001075A MX 2010001075 A MX2010001075 A MX 2010001075A
Authority
MX
Mexico
Prior art keywords
piperidin
ylmethyl
amide derivatives
uptake inhibitors
monoamine neurotransmitter
Prior art date
Application number
MX2010001075A
Other languages
English (en)
Inventor
Dan Peters
Elsebet Oestergaard Nielsen
Birgitte L Eriksen
John Paul Redrobe
Gordon Munro
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Publication of MX2010001075A publication Critical patent/MX2010001075A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta invención se relaciona con derivados de N-piperidin-4-ilmetil amida novedosos útiles como inhibidores de la recaptación de neurotransmisores de monoamina. En otros aspectos la invención se relaciona con el uso de estos compuestos en un método para terapia, y con composiciones farmacéuticas que comprenden los compuestos de la invención.
MX2010001075A 2007-08-02 2008-07-31 Derivados de n-piperidin-4-ilmetil-amida y su uso como inhibidores de recaptacion del neurotransmisor de monoamina. MX2010001075A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200701113 2007-08-02
US95375307P 2007-08-03 2007-08-03
PCT/EP2008/060033 WO2009016214A2 (en) 2007-08-02 2008-07-31 N-piperidin-4-ylmethyl-amide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Publications (1)

Publication Number Publication Date
MX2010001075A true MX2010001075A (es) 2010-03-09

Family

ID=39832221

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001075A MX2010001075A (es) 2007-08-02 2008-07-31 Derivados de n-piperidin-4-ilmetil-amida y su uso como inhibidores de recaptacion del neurotransmisor de monoamina.

Country Status (8)

Country Link
US (1) US20100204275A1 (es)
EP (1) EP2183219A2 (es)
JP (1) JP2010535174A (es)
CN (1) CN101796027A (es)
AU (1) AU2008281766A1 (es)
CA (1) CA2695496A1 (es)
MX (1) MX2010001075A (es)
WO (1) WO2009016214A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2183240A2 (en) * 2007-08-02 2010-05-12 NeuroSearch AS N-aryl-n-piperidin-4-ylmethyl-amide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP2235006A1 (en) * 2007-12-19 2010-10-06 NeuroSearch A/S N-aryl-n-piperidin-4-yl-propionamide derivatives and their use as opioid receptor ligands
CN102656151A (zh) * 2009-09-04 2012-09-05 扎里卡斯药品有限公司 治疗疼痛和癫痫的取代的杂环衍生物
US9637470B2 (en) * 2013-02-22 2017-05-02 Baylor College Of Medicine Treatment for substance use disorders and stress disorders
US10208023B2 (en) 2013-03-01 2019-02-19 Mark G. DeGiacomo Heterocyclic inhibitors of the sodium channel

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US6189045B1 (en) * 1998-03-26 2001-02-13 International Business Machines Corp. Data type conversion for enhancement of network communication systems
DE10132746A1 (de) * 2001-07-05 2003-02-06 Gruenenthal Gmbh Substituierte 1-Phenethylpiperidinverbindungen
GB0408772D0 (en) * 2004-04-20 2004-05-26 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
EP2183219A2 (en) 2010-05-12
AU2008281766A1 (en) 2009-02-05
CN101796027A (zh) 2010-08-04
JP2010535174A (ja) 2010-11-18
CA2695496A1 (en) 2009-02-05
WO2009016214A2 (en) 2009-02-05
WO2009016214A3 (en) 2009-06-18
US20100204275A1 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
MX2010001754A (es) Derivados de azepina como inhibidores de gamma secretasa.
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
AU2009303758A8 (en) Benzoquinoline inhibitors of vesicular monoamine transporter 2
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
MY153915A (en) Organic compounds
MX2012004780A (es) Inhibidores de akt.
MX354402B (es) Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos.
IN2012DN01233A (es)
MX2010008714A (es) Derivados de amida como moduladores alostericos positivos y metodos de uso de los mismos.
UA98804C2 (ru) Катехоламиновые производные и фармацевтическая композиция на их основе
MY161461A (en) Akt and p70 s6 kinase inhibitors
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
IL205696A0 (en) Heterocyclic derivatives, compositions comprising the same and uses thereof
WO2004113297A3 (en) Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
TW200738714A (en) New secondary amines
MX2009005916A (es) Nuevos derivados de cromen-2-ona y su uso como inhibidores de la reabsorcion del neurotransmisor de monoamina.
MX2010009147A (es) Derivados de pirrolidinilo y usos de los mismos.
TW200800980A (en) Novel compounds
PL1797088T3 (pl) Nowe pochodne chromen-2-onu i ich zastosowanie jako inhibitorów wychwytu zwrotnego neurotransmiteru monoaminowego
TW200800940A (en) New primary amines
MX2010001075A (es) Derivados de n-piperidin-4-ilmetil-amida y su uso como inhibidores de recaptacion del neurotransmisor de monoamina.
DK2271638T3 (da) Modulatorer af dopaminneurotransmission
TW200604173A (en) Novel compounds
MX2009006213A (es) Nuevos derivados de cromen-2-ona y su uso como inhibidores de reabsorcion del neurotransmisor monoamina.
WO2010023197A3 (en) Piperidine-4-acetamide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Legal Events

Date Code Title Description
HH Correction or change in general